Despite modest clinical outcomes from prior trials of IGF1R inhibitors in other cancers [31], the robust association between IGF1R expression and patient survival in CCA suggests that selecting patients based on IGF1R status could effectively enrich for therapeutic responders. The gene discussed is IGF1R; the disease is cancer.